Hamza F, Mohammad K
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770433
PMC: 11679356.
DOI: 10.3390/ph17121591.
Song C, Tong T, Dai B, Zhu Y, Chen E, Zhang M
J Natl Cancer Cent. 2024; 4(4):354-368.
PMID: 39735445
PMC: 11674455.
DOI: 10.1016/j.jncc.2024.09.001.
Whitman M, Mantri M, Spanos E, Estroff L, De Vlaminck I, Fischbach C
Biomaterials. 2024; 315:122916.
PMID: 39490060
PMC: 11658005.
DOI: 10.1016/j.biomaterials.2024.122916.
Wilson T, Zishiri O
Cancer Rep (Hoboken). 2024; 7(10):e70016.
PMID: 39410867
PMC: 11480670.
DOI: 10.1002/cnr2.70016.
He Y, Li G, Wu Y, Cai N, Chen Z, Mei B
Discov Oncol. 2024; 15(1):503.
PMID: 39333441
PMC: 11436596.
DOI: 10.1007/s12672-024-01388-0.
Bone mineral density affects tumor growth by shaping microenvironmental heterogeneity.
Whitman M, Mantri M, Spanos E, Estroff L, De Vlaminck I, Fischbach C
bioRxiv. 2024; .
PMID: 39091735
PMC: 11291034.
DOI: 10.1101/2024.07.19.604333.
Extracellular Vesicles from Highly Metastatic Osteosarcoma Cells Induce Pro-Tumorigenic Macrophage Phenotypes.
Griffin K, Mizenko R, Arun V, Carney R, Leach J
Adv Biol (Weinh). 2024; 8(6):e2300577.
PMID: 38596830
PMC: 11178448.
DOI: 10.1002/adbi.202300577.
Glycolysis-cholesterol metabolic axis in immuno-oncology microenvironment: emerging role in immune cells and immunosuppressive signaling.
Jin J, Zhao Q, Wei Z, Chen K, Su Y, Hu X
Cell Biosci. 2023; 13(1):189.
PMID: 37828561
PMC: 10571292.
DOI: 10.1186/s13578-023-01138-9.
Engineered bone marrow as a clinically relevant ex vivo model for primary bone cancer research and drug screening.
Griffin K, Thorpe S, Sebastian A, Hum N, Coonan T, Sagheb I
Proc Natl Acad Sci U S A. 2023; 120(39):e2302101120.
PMID: 37729195
PMC: 10523456.
DOI: 10.1073/pnas.2302101120.
YTHDF3as a prognostic predictive biomarker of thyroid cancer and its correlation with immune infiltration.
Zhang Y, Chen Y, Chen R, Zhou H, Lin Y, Li B
BMC Cancer. 2023; 23(1):882.
PMID: 37726690
PMC: 10507848.
DOI: 10.1186/s12885-023-11361-9.
Immune responses of six-transmembrane epithelial antigen of the prostate 4 functions as a novel biomarker in gastric cancer.
Fang Z, Hou Y, Wu Z, Wu B, Deng Y, Wu H
World J Clin Oncol. 2023; 14(8):297-310.
PMID: 37700807
PMC: 10494559.
DOI: 10.5306/wjco.v14.i8.297.
Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma.
Chen X, Yi G, Zhou Y, Hu W, Xi L, Han W
Mediators Inflamm. 2023; 2023:4926474.
PMID: 37124063
PMC: 10137198.
DOI: 10.1155/2023/4926474.
STAT2 act a prognostic biomarker and associated with immune infiltration in kidney renal clear cell carcinoma.
Zeng T, Ye J, Wang H, Tian W
Medicine (Baltimore). 2023; 102(17):e33662.
PMID: 37115061
PMC: 10146042.
DOI: 10.1097/MD.0000000000033662.
EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K, Zhang B, Han D, Sun Y
BMC Bioinformatics. 2023; 24(1):149.
PMID: 37069494
PMC: 10111667.
DOI: 10.1186/s12859-023-05271-7.
Comprehensive analysis reveals CCDC60 as a potential biomarker correlated with prognosis and immune infiltration of head and neck squamous cell carcinoma.
Liu Z, Chen S, Jia W, Qian Y, Yang X, Zhang M
Front Oncol. 2023; 13:1113781.
PMID: 37064086
PMC: 10098326.
DOI: 10.3389/fonc.2023.1113781.
ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma.
Xu L, Zhang S, Feng J, Tan D, Sun H, Guo H
Cancer Cell Int. 2023; 23(1):44.
PMID: 36899391
PMC: 10007768.
DOI: 10.1186/s12935-023-02869-y.
Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma.
Jia M, Liu C, Liu Y, Bao Z, Jiang Y, Sun X
J Pers Med. 2023; 13(1).
PMID: 36675674
PMC: 9866779.
DOI: 10.3390/jpm13010013.
Macrophage-Specific Cathepsin as a Marker Correlated with Prognosis and Tumor Microenvironmental Characteristics of Clear Cell Renal Cell Carcinoma.
Zhang F, Liang J, Lu Y, Tang Y, Liu S, Wu K
J Inflamm Res. 2022; 15:6275-6292.
PMID: 36386587
PMC: 9664926.
DOI: 10.2147/JIR.S375250.
ZNF521 Is Correlated with Tumor Immune Cell Infiltration and Act as a Valuable Prognostic Biomarker in Gastric Cancer.
Li L, Liu Z, Wang H, Wang L, Ru G, Wang Y
Gastroenterol Res Pract. 2022; 2022:5288075.
PMID: 36311294
PMC: 9606838.
DOI: 10.1155/2022/5288075.
PLK4 Is a Potential Biomarker for Abnormal Tumor Proliferation, Immune Infiltration, and Prognosis in ccRCC.
Hu C, Liu Q, Hu C, Wang Y, Wang P, Zhou X
Comput Math Methods Med. 2022; 2022:6302234.
PMID: 36176741
PMC: 9514917.
DOI: 10.1155/2022/6302234.